Genedrive : 2018 Annual Report and AGM Notice

For release: 7 December 2018

2018 Annual Report and AGM Notice

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, gives notice that copies of its 2018 Annual Report and Notice of the 2018 Annual General Meeting have been posted to shareholders. The AGM will be held at 11:00 on 31 December 2018 at the offices of Addleshaw Goddard LLP, Milton Gate, 60 Chiswell Street, London, EC1Y 4AG.

Copies of these documents may be found on the Company's website (www.genedriveplc.com)

- Ends -

For further details please contact:

genedrive plc	[phone]
David Budd: CEO
Matthew Fowler: CFO
Peel Hunt LLP
James Steel	[phone]
Oliver Jackson
Stanford Capital Partners Limited Patrick Claridge	[phone]	[phone]
John Howes
Consilium Strategic Communications	[phone]
Chris Gardner	[e-mail]
Matthew Neal
Laura Thornton

Notes to Editors

About genedrive plc

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® HCV-ID test has received CE-IVD Certification and has been launched in Africa and Asia Pacific. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA and SE Asia (ex-India), and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive® HCV-ID Kit and Genedrive® platform in India. Further details can be found at: www.genedriveplc.com andwww.genedrive.com. The Company also has tests in development for tuberculosis (mTB) and Antibiotic Induced Hearing Loss (AIHL).